Sign in Register

Drug class

Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody

A vascular endothelial growth factor (VEGF) monoclonal antibody is a targeted biologic agent engineered to bind specifically to VEGF ligands (such as VEGF-A) or their corresponding receptors (primarily VEGFR-2). Read more about Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody

8 drugs in this class 8 manufacturers

Related classes & indications

Antirheumatic Agents (Biologic DMARDS)Biologics, antibodies & cell therapy · 170 prescription drugs Immunomodulator, B-Lymphocyte Stimulator (BLyS)-Spec InhibBiologics, antibodies & cell therapy · 38 prescription drugs

Showing 1–8 of 8 drugs

Sort

AVASTIN (bevacizumab)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+6

GENENTECH

CYRAMZA (ramucirumab)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+5

Eli Lilly and Company

MVASI (bevacizumab-awwb)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+5

AMGEN

ZIRABEV (bevacizumab-bvzr)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+5

Parke-Davis Pfizer

ALYMSYS (bevacizumab-maly)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+5

Amneal Pharmaceuticals

VEGZELMA (bevacizumab-adcd)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+5

CELLTRION USA,

JOBEVNE (bevacizumab-nwgd)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+5

BIOCON BIOLOGIC

ALYMSYS (bevacizumab-maly)

VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) MONOCLONAL ANTIBODY · METASTATIC COLORECTAL CANCER ·+5

VALORUM BIOLOGI

Filter & compare in the drug finder → Opens the drug finder with Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody preselected. Add indication or manufacturer filters there.

About Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody.

A vascular endothelial growth factor (VEGF) monoclonal antibody is a targeted biologic agent engineered to bind specifically to VEGF ligands (such as VEGF-A) or their corresponding receptors (primarily VEGFR-2).

By neutralizing circulating growth factor or blocking its receptor activation, these antibodies suppress downstream signaling cascades essential for endothelial cell proliferation, migration, and capillary formation.

This anti-angiogenic mechanism inhibits pathological neovascularization and reduces vascular permeability.

Clinically, drugs in this class—most notably bevacizumab and ramucirumab—are primarily indicated in oncology for treating advanced solid malignancies, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and gastric cancer.

Related antibody formulations and fragments are also widely utilized in ophthalmology to manage neovascular retinal diseases such as wet age-related macular degeneration and diabetic macular edema.

fda.gov
A vascular endothelial growth factor (VEGF) monoclonal antibody is a targeted biologic agent engineered to bind specifically to VEGF ligands (such as VEGF-A) or their corresponding receptors (primarily VEGFR-2)
cancer.gov
A vascular endothelial growth factor (VEGF) monoclonal antibody is a targeted biologic agent engineered to bind specifically to VEGF ligands (such as VEGF-A) or their corresponding receptors (primarily VEGFR-2)
fda.gov
By neutralizing circulating growth factor or blocking its receptor activation, these antibodies suppress downstream signaling cascades essential for endothelial cell proliferation, migration, and capillary formation
fda.gov
By neutralizing circulating growth factor or blocking its receptor activation, these antibodies suppress downstream signaling cascades essential for endothelial cell proliferation, migration, and capillary formation
fda.gov
This anti-angiogenic mechanism inhibits pathological neovascularization and reduces vascular permeability Related antibody formulations and fragments are also widely utilized in ophthalmology to manage neovascular retinal diseases such as wet age-related macular degeneration and diabetic macular edema
cancer.gov
This anti-angiogenic mechanism inhibits pathological neovascularization and reduces vascular permeability
fda.gov
Clinically, drugs in this class—most notably bevacizumab and ramucirumab—are primarily indicated in oncology for treating advanced solid malignancies, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and gastric cancer
cancer.gov
Clinically, drugs in this class—most notably bevacizumab and ramucirumab—are primarily indicated in oncology for treating advanced solid malignancies, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and gastric cancer
cancer.gov
Clinically, drugs in this class—most notably bevacizumab and ramucirumab—are primarily indicated in oncology for treating advanced solid malignancies, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and gastric cancer
fda.gov
Related antibody formulations and fragments are also widely utilized in ophthalmology to manage neovascular retinal diseases such as wet age-related macular degeneration and diabetic macular edema